Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 4, 2000, Pages 427-431

  Buemi, Michele ^a   Allegra, Alessandro ^b   Corica, Francesco ^b   Aloisi, Carmela ^b   Giacobbe, MariaStella ^b   Pettinato, Giuseppina ^b   Corsonello, Andrea ^b   Senatore, Massimino ^b   Frisina, Nicola ^b  

^a NONE   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN A; PLACEBO;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GLOMERULOSCLEROSIS; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PROTEINURIA; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034069293     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.105330     Document Type: Article

References (22)

1. 1. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992;33:1569-82.
2. 2. Kasiske BL, O'Donnell MP, Clearly MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988;33:667-72.
3. 3. Harris KPG, Purkerson ML, Yates J, Klahr S. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 1990;15:16-23.
4. 4. O'Donnell MP, Kasiske BL, Schmitz PG, Keane WF. Lovastatin retards the progression of established renal disease in obese Zucker rats. Am J Kidney Dis 1993;22:83-9.
5. 5. Lee SK, Jin SY, Han DC, Hwang SD, Lee HB. Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats. Nephrol Dial Transplant 1993;8:1338-43.
6. 6. Massy ZA, Guijarro C, O'Donnell MP, Kasiske BL, Keane WF. Lipides, inhobiteurs de la 3-hydroxy-3-méthyl glutaryl coenzyme a rèductase et progression de l'insuffisance rènale. In: Hamburger J. Actualitès Nèphrologiques. Paris: Flammarion Medecine Sciences; 1997. p. 129-42.
7. 7. Pirani CL, Solinas-Madrigal L. Evaluation of percutaneous renal biopsy. Pathol A 1968;3:249-96.
8. 8. Grandaliano G, Biswas P, Choudhury GC, Abboud HE. Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int 1993;44: 503-8.
9. 9. Buemi M, Allegra A, Senatore M, Marino D, Medici MA, Aloisi C, et al. Pro-apoptotic effect of fluvastatin on human muscle cells. Eur J Pharmacol 1999;370:201-3.
10. 10. Nagata M, Akioka Y, Tsunoda Y, Komatsu Y, Kawaguchi H, Yamaguchi Y, et al. Macrophages in childhood IgA nephropathy. Kidney Int 1995;48:527-35.
11. 11. Miyazaki K, Isbel NM, Lan HY, Hattori M, Bacher M, Bucala R, et al. Up-regulation of macrophage colony-stimulating factor (M-CSF) and migration inhibitory factor (MIF) expression and monocyte recruitment during lipid-induced glomerular injury in the exogenous hypercholesterolemic (ExHC) rat. Clin Exp Immunol 1997;108:318-23.
12. 12. Guijarro C, Keane WF. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Miner Electrolyte Metab 1996;22:147-52.
13. 13. Park SY. Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 1998;1: 190-4.
14. 14. Mene P, Simonson MS, Dunn MJ. Physiology of the mesangial cell. Physiol Rev 1989;69:1374-424.
15. 15. Johnson RJ, Raines EW, Floege J, Yoshimura A, Pritzl P, Alpers C, et al. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 1992;175:1413-6.
16. 16. Choi KH, Kang SW, Lee SW, Lee HY, Han DS, Kang BS. The effect of Lovastatin on proliferation of cultured rat mesangial and aortic smooth cells. Yonsei Med J 1995;36:251-61.
17. 17. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95: 1126-31.
18. 18. Senatore M, Buemi M. HMG-CoA reductase inhibitors and apoptosis. Nephron 1999;81:439-40.
19. 19. Sindermann J, Weigel K, Muller JG, Breithard G. Lovastatin causes downregulation of cyclic-dependent kinase 2, upregulation of tyrosine phosphorylation and is capable of inducing apoptosis in human, bovine and rat vascular smooth muscle cells [abstract]. Circulation 1996; 94:639.
20. 20. Baker AJ, Mooney A, Hughes J, Lombardi D, Johnson RJ, Savill J. Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J Clin Invest 1994;94:2105-16.
21. 21. Buemi M, Allegra A, Corica F, Ruello A, Aloisi C, Pettinato G, et al. Effects of lisinopril administration on blood bcl-2 concentrations in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 1999;65:649-52.
22. 22. Savill J. Apoptosis and the kidney. J Am Soc Nephrol 1994;5:12-21.